Allele Biotechnology & Pharmaceuticals announced participation in an ARPA‑H funded project with UC San Diego aimed at developing a fully functional, patient‑specific 3D‑bioprinted liver for transplantation. The award could be up to $25.8 million and targets scalable tissue manufacturing to address liver transplant shortages. The project combines Allele’s cell‑manufacturing and technology development capabilities with academic research at UCSD to design vascularized, functional liver constructs suitable for transplantation. ARPA‑H framed the initiative as a high‑risk, high‑reward effort to create organ replacements that could expand transplant access. If successful, the program could shift organ supply paradigms and create new regulatory and manufacturing pathways for implantable, patient‑matched bioprinted organs.